Executive Summary
The competitive business environment for the pharmaceutical market of chronic hepatitis C virus (HCV) infection is fierce and changing. The entry of Hoffmann-La Roche into this $3 billion market, previously dominated by Schering-Plough, has certainly paved the way and will make life easier for other HCV drug developing companies. Competition is healthy, and market dominance by one big pharma provides far fewer business opportunities compared to two companies fighting to be the world leader.
The race is on and due to the limitations of current treatment for chronic hepatitis C virus infection, a lot of R&D activities are spent on novel therapeutic strategies targeting events specific to viral replication. A number of newer therapies, including protease and helicase inhibitors, ribozymes, antisense therapies, and therapeutic vaccines, are in preclinical or clinical development and may significantly enhance existing therapeutic options for the future.
BioSeeker has in this report taken a fresh look on both the current world status of R&D and business development in HCV. Our research and analysis is built on more than 150 companies from over 18 different countries and include more than 160 pipline drugs in development for HCV.
We give you an up to date outline of the HCV competitive landscape, involving 66 selected collaborations divided into 7 major clusters of companies, whereof six are interconnected and one cluster stands alone. Find out key data on each cluster, such as Type of Collaboration (9 classes), R&D Focus, Number of Drugs in Development, Competitive Edge etc. BioSeeker’s competitive analysis sheds light and increases understanding of alliances that future partners are involved in, so that you can minimize the risk that competitors can gain information about what you are planning to do.
BioSeeker’s HCV R&D analysis thoroughly discusses drug and vaccine development world wide. The analysis covers more than 108 pipeline drugs, ranging from pre-clinical to phase III. Key points in the analysis are to deduce trends in HCV drug development, evaluate all major drug targets and outline country by country efforts in HCV. The analysis also addresses the issue of what demands are raised on new HCV drugs and how the industry gradually will move over from interferon to small molecular drugs and combination therapies thereof. Special emphasis is put on linking analysis with concrete R&D projects through high value tables, in order to facilitate further research.
This report has been written for people in business development, competitive intelligence, and for R&D project responsibles in HCV. We do also believe that this report is suitable for CEOs, especially in smaller sized companies.
Executive Summary
Methodology
Information Sources
Selection of Companies
Continents
Cluster Definitions and Limitations
R&D Definitions and Limitations
Analysts
Abbreviations
Introduction
Hepatitis C
Transmission
Genotypes
Current Drugs and Therapies targeting HCV
Pegylation Improves Efficacy and Administration
The Launch of Generic Ribavirin
Disturbing Side Effects
Drug Development Obstacles and Promises
HCV Market Development - A Multibillion Market Facing Changes
HCV Pharmaceutical Market in for a Stagnation in Growth
The Battle of Equals in Interferon - Affects the Entire HCV Market
How Schering-Plough Wants to Regain World Leadership After Loosing the 1st Round to Roche- The 2nd Round
World Business Interest in HCV
The Competitive Landscape of HCV Alliances
Companies Between Powerful Clusters - Are They of Strategic Value?
The HCV Cluster Analysis
Cluster I: The Screening Cluster
Cluster II: Out-licensing as a Business Model for HCV
Cluster III: The RNA Drug Discovery Creates Interest
Cluster IV: Future Success Lies in Co-Development?
Cluster V: Cluster of a Market Leader
Cluster VI: A Phase II Drug Cluster
Cluster VII: Cluster of Small Pharma: Do They Challenge?
Singles or Non-cluster HCV Companies?
R&D Diversity in HCV
Just About How Innovative is the Industry?
World Review on HCV Drug & Vaccine Development
Introduction
Top Five Countries
Latest Progress on Animal Models - Do they deliver?
Surrogate Animal Models
Human-Mice Chimeric Models
Using Stem-Cells
Transgenic Models
Pharmaceutical Drug Development
What Demands are Raised on New HCV Drugs?
Interferon will Continue to Dominate - But for How Long?
Ongoing Strategies to Enhance Interferon-based Therapies
Oral Interferon Inducers
Other Therapies That Modulate Host Immune Responses
Anti-HCV immunoglobulins - How do They Evolve?
The Power of HCV Inhibitors
Status and Advancement of RNA dependent RNA polymerase inhibitor
Status and Advancement of Serine-protease inhibitor
Status and Advancement of IMPDH inhibitor
Status and Advancement of P7 inhibitors
Is the Future Small Molecular Drugs?
Gene and Cell therapy Programs - An Alternative Route for Fighting HCV?
Ribozymes - Targets and Mechanisms in fighting HCV
The Never Ending Fight in Fibrosis
Non-Survival Drugs and Drugs on Hold
Mechanism versus Target - An Inventory of the Current Status
Partnering in HCV Drug Development
Progress in Prophylactic and Therapeutic HCV Vaccine Development
Prophylactic Vaccines Development
With a Strong Alliance in the DNA Vaccine Business
Therapeutic Vaccine Development
Who Will Be First With a Vaccine?
Partnering in HCV Prophylactic and Therapeutic Vaccine Development
Conclusion
Disclaimer
Liability
Completeness
Appendix A. Selected Key Company Profiles
Akros Pharma Inc
Anadys Pharmaceuticals
Boehringer Ingelheim GmbH
Chiron Corporation
F Hoffmann-La Roche
Collaborations
Hayashibara Biochemical Laboratories Inc
HemispheRx Biopharma
Indevus Pharmaceuticals Inc
Innogenetics NV/SA
InterMune Pharmaceuticals Inc
ISIS Pharmaceuticals Inc
Mitsubishi Pharma Corporation
Nektar Therapeutics
Schering-Plough Corporation
SciClone Pharmaceuticals Inc
Serono International S.A.
Tripep AB
Valeant Pharmaceuticals International
Viragen, Inc.
XTL Biopharmaceuticals Ltd
Akros Pharma Inc
Anadys Pharmaceuticals
Boehringer Ingelheim GmbH
Chiron Corporation
F Hoffmann-La Roche
Collaborations
Hayashibara Biochemical Laboratories Inc
HemispheRx Biopharma
Indevus Pharmaceuticals Inc
Innogenetics NV/SA
InterMune Pharmaceuticals Inc
ISIS Pharmaceuticals Inc
Mitsubishi Pharma Corporation
Nektar Therapeutics
Schering-Plough Corporation
SciClone Pharmaceuticals Inc
Serono International S.A.
Tripep AB
Valeant Pharmaceuticals International
Viragen, Inc.
XTL Biopharmaceuticals Ltd
Other selected research from the 'Business Development' category:
Partnering Agreements with Merck & Co 2010
This report provides all the information you require to better understand Merck & Co Labs and its partnering interests and activities over the past five years. Learn More
Partnering Agreements with UCB 2010
This report provides all the information you require to better understand UCB Labs and its partnering interests and activities over the past five years. Learn More
Other selected research from the 'R&D' category:
Analytical Tool - Lymphoma
IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2012
Other selected research from the 'Infectious diseases' category:
The Antibacterial Drug Market Analysis 2008-2013
Promising Drug Discovery Tools in Antifungal and Status on Emerging Novel Targets